These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

67 related articles for article (PubMed ID: 24304257)

  • 1. FDA warning and removal of rosiglitazone from VA national formulary.
    Aspinall SE; Zhao X; Good CB; Stone RA; Smith KJ; Cunningham FE
    Am J Manag Care; 2013 Sep; 19(9):748-58. PubMed ID: 24304257
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Geographic Variation in Rosiglitazone Use Surrounding FDA Warnings in the Department of Veterans Affairs.
    Ahuja V; Sohn MW; Birge JR; Syverson C; Budiman-Mak E; Emanuele N; Cooper JM; Huang ES
    J Manag Care Spec Pharm; 2015 Dec; 21(12):1214-34. PubMed ID: 26679970
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical consequences of disseminating the rosiglitazone FDA safety warning.
    Orrico KB; Lin JK; Wei A; Yue H
    Am J Manag Care; 2010 May; 16(5):e111-6. PubMed ID: 20455636
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Disparities in Discontinuing Rosiglitazone Following the 2007 FDA Safety Alert.
    Qato DM; Trivedi AN; Mor V; Dore DD
    Med Care; 2016 Apr; 54(4):406-13. PubMed ID: 26978569
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antidiabetic prescribing trends and predictors of thiazolidinedione discontinuation following the 2007 rosiglitazone safety alert.
    Hurren KM; Taylor TN; Jaber LA
    Diabetes Res Clin Pract; 2011 Jul; 93(1):49-55. PubMed ID: 21440324
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The rosiglitazone decision process at FDA and EMA. What should we learn?
    Pouwels KB; van Grootheest K
    Int J Risk Saf Med; 2012; 24(2):73-80. PubMed ID: 22751189
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intervention to decrease glyburide use in elderly patients with renal insufficiency.
    Aspinall SL; Zhao X; Good CB; Stone RA; Boresi J; Cox S; Bartholomew C; Jansen D; Guterman S; Patino M; Rivera-Miranda G; Burlingame M; Frazer J; Sellers J; Stanard Steele V; Witt L; Cunningham FE
    Am J Geriatr Pharmacother; 2011 Feb; 9(1):58-68. PubMed ID: 21459309
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The thiazolidinediones rosiglitazone and pioglitazone and the risk of coronary heart disease: a retrospective cohort study using a US health insurance database.
    Ziyadeh N; McAfee AT; Koro C; Landon J; Arnold Chan K
    Clin Ther; 2009 Nov; 31(11):2665-77. PubMed ID: 20110009
    [TBL] [Abstract][Full Text] [Related]  

  • 9. FDA puts rosiglitazone post-marketing trial on hold.
    Cohen D
    BMJ; 2010 Jul; 341():c4017. PubMed ID: 20660507
    [No Abstract]   [Full Text] [Related]  

  • 10. Warnings without guidance: patient responses to an FDA warning about ezetimibe.
    Shrank WH; Choudhry NK; Tong A; Myers J; Fischer MA; Swanton K; Slezak J; Brennan TA; Liberman JN; Moffit S; Avorn J; Carpenter D
    Med Care; 2012 Jun; 50(6):479-84. PubMed ID: 22581012
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The rise and fall of the thiazolidinediones: impact of clinical evidence publication and formulary change on the prescription incidence of thiazolidinediones.
    Hashim S; Gomes T; Juurlink D; Hellings C; Mamdani M
    J Popul Ther Clin Pharmacol; 2013; 20(3):e238-42. PubMed ID: 24141901
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of regulatory labeling for troglitazone and rosiglitazone on hepatic enzyme monitoring compliance: findings from the state of Ohio medicaid program.
    Cluxton RJ; Li Z; Heaton PC; Weiss SR; Zuckerman IH; Moomaw CJ; Hsu VD; Rodriguez EM
    Pharmacoepidemiol Drug Saf; 2005 Jan; 14(1):1-9. PubMed ID: 15546159
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Trends in Incident Varenicline Prescribing Among Veterans Following the US Food and Drug Administration Drug Safety Warnings.
    Gerlach LB; Van T; Kim HM; Chang MM; Bohnert KM; Zivin K
    J Clin Psychiatry; 2021 Dec; 83(1):. PubMed ID: 34936245
    [No Abstract]   [Full Text] [Related]  

  • 14. FDA advisers recommend new controls on rosiglitazone use.
    Traynor K
    Am J Health Syst Pharm; 2010 Aug; 67(16):1306-8. PubMed ID: 20689113
    [No Abstract]   [Full Text] [Related]  

  • 15. Rosiglitazone, myocardial ischemic risk, and recent regulatory actions.
    Bourg CA; Phillips BB
    Ann Pharmacother; 2012 Feb; 46(2):282-9. PubMed ID: 22298606
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of cardiovascular outcomes in elderly patients with diabetes who initiated rosiglitazone vs pioglitazone therapy.
    Winkelmayer WC; Setoguchi S; Levin R; Solomon DH
    Arch Intern Med; 2008 Nov; 168(21):2368-75. PubMed ID: 19029503
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Temporal trends in anti-diabetes drug use in TRICARE following safety warnings in 2007 about rosiglitazone.
    Stewart KA; Natzke BM; Williams T; Granger E; Casscells SW; Croghan TW
    Pharmacoepidemiol Drug Saf; 2009 Nov; 18(11):1048-52. PubMed ID: 19655338
    [TBL] [Abstract][Full Text] [Related]  

  • 18. FDA hearings leave doctors, patients in limbo on Avandia.
    Eggertson L; Woodward C
    CMAJ; 2010 Sep; 182(12):E559-60. PubMed ID: 20660583
    [No Abstract]   [Full Text] [Related]  

  • 19. Association between FDA black box warnings and Medicare formulary coverage changes.
    Dhruva SS; Karaca-Mandic P; Shah ND; Shaw DL; Ross JS
    Am J Manag Care; 2017 Sep; 23(9):e310-e315. PubMed ID: 29087169
    [TBL] [Abstract][Full Text] [Related]  

  • 20. FDA on rosiglitazone. More on advisory committee decision.
    Graham DJ; Gelperin K
    BMJ; 2010 Sep; 341():c4868. PubMed ID: 20823021
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.